Non-alcoholic fatty liver disease (NAFLD), which is characterized by excessive fat accumulation in the liver in people without excessive alcohol use, affects approximately one fourth of the global and South Korean populations (Araujo et al., 2018;Bellentani, 2017;Kwak & Kim, 2018). Once NAFLD has progressed, it is irreversible and can lead to liver fibrosis, cirrhosis or hepatocellular carcinoma (European Association for the Study of the Liver, 2016). The progression of NAFLD not only imposes a clinical burden on patients but also affects their survival rate and quality of life (Perumpail et al., 2017;Younossi & Henry, 2015). A recent study reported NAFLD-related cirrhosis and hepatocellular carcinoma as the second leading cause of liver transplantation in the United States (Bellentani, 2017).Further, studies have demonstrated that people with NAFLD have a higher mortality rate than the general population (Bellentani, 2017;European Association for the Study of the Liver, 2016).Unlike alcoholic fatty liver disease, for which the main risk factor is excessive alcohol consumption, risk factors for NAFLD include obesity, dyslipidaemia and type 2 diabetes. However, in the absence of a pharmacological therapy, NAFLD treatment is focused on metabolic profile improvement (Araujo et al., 2018;Bellentani, 2017).Clinical guidelines for managing NAFLD emphasize lifestyle modification, which includes a low-calorie diet; lower intake of refined carbohydrates, fat and sugar; and increased physical activity (European Association for the Study of the Liver, 2016;Katsagoni et al., 2017). This suggests that patients with NAFLD require lifetime disease monitoring and management.